Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Decreases By 52.0%

Mustang Bio, Inc. (NASDAQ:MBIO) was the recipient of a large drop in short interest in the month of March. As of March 15th, there was short interest totalling 44,000 shares, a drop of 52.0% from the February 28th total of 91,700 shares. Approximately 2.8% of the shares of the stock are short sold. Based on an average trading volume of 316,300 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Mustang Bio

A hedge fund recently raised its stake in Mustang Bio stock. Geode Capital Management LLC grew its stake in Mustang Bio, Inc. (NASDAQ:MBIO) by 15.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 284,437 shares of the company’s stock after purchasing an additional 38,951 shares during the quarter. Geode Capital Management LLC owned approximately 29.63% of Mustang Bio worth $50,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.95% of the company’s stock.

Mustang Bio Price Performance

NASDAQ MBIO traded down $0.09 during trading hours on Friday, reaching $1.33. The company’s stock had a trading volume of 73,124 shares, compared to its average volume of 244,964. The firm has a market capitalization of $1.27 million, a price-to-earnings ratio of -0.02 and a beta of 1.82. The company’s 50-day moving average is $2.65 and its two-hundred day moving average is $8.07. Mustang Bio has a 1-year low of $1.28 and a 1-year high of $65.00.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.